Abstract WP097: A Multidisciplinary Clinic Model Provides Coordinated Care, Biomarker Integration, and Clinical Trial Access in Cerebral Amyloid Angiopathy

Background: Cerebral amyloid angiopathy (CAA) is a heterogeneous small vessel disease with presentations including intracerebral hemorrhage, transient focal neurological episodes and cognitive decline, often with overlapping Alzheimer’s Disease-related pathology. In June 2024, we established a multidisciplinary CAA clinic integrating Vascular and Cognitive Neurology to provide individualized risk assessment, diagnostic precision, and longitudinal management. Services include psychometric testing, advanced imaging, biomarker analysis, structured patient–caregiver education, and support from a clinic coordinator and social worker. We also aimed to increase institutional awareness and access to available clinical trials. This report summarizes the first year of clinic operations. Methods: We analyzed all patients seen from June 2024 to July 2025. Referrals came via standard in-network pathways, with out-of-network or out-of-state via clinic email. Data were prospectively captured at the point of care using an EMR-integrated tool. A subset of patients participated in an integrative, same-day visit with Vascular Neurology, Cognitive Neurology, psychometric testing, and a structured family/caregiver debrief. Advanced diagnostics—including serum or CSF amyloid (A), tau (T), neurodegeneration (N) biomarkers, APOE genotyping, and amyloid PET—were obtained when indicated. Results: During the 12-month period, 200 unique patients were evaluated in the CAA Clinic. A total of 48%(N=96) of visits followed the integrative same-day model, and 8% (N=16) of patients were enrolled in clinical trials during the study period. Overall, 17% (N=34) of patients completed APOE genotyping, 77.5% (N=155) completed ATN biomarker testing, 32.5 % (N=65) received amyloid PET imaging, and 67% (N=133) received full psychometric analysis. Detailed demographics, diagnostic distributions, biomarker completion rates, imaging characteristics, and cognitive outcomes are presented in Tables 1–3. Conclusions: A multidisciplinary CAA clinic is feasible in a tertiary setting and enables comprehensive characterization of a diverse patient population. Integration of Vascular and Cognitive Neurology expertise with advanced diagnostics and prospective EMR capture supports individualized, longitudinal management while also facilitating clinical trial participation.